UWS
ALNY icon

Unique Wealth Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Unique Wealth Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,854
Closed -$613K – 224
2026
Q1 		$613K Buy
+1,854
New +$631K 0.25% 108
2024
Q4 		– Sell
-1,899
Closed -$522K – 191
2024
Q3 		$522K Buy
1,899
+1,876
+8,157% +$488K 0.22% 121
2024
Q2 		$3.44K Buy
+23
New +$3.63K ﹤0.01% 417

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return

Unique Wealth Strategies's ALNY Position: Q2 2026 in Review

Unique Wealth Strategies sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1,854 shares — an estimated $613K sold.

Unique Wealth Strategies first reported a position in ALNY in Q2 2024 and held it in 3 quarters. The position peaked at $613K in Q1 2026. 96 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Unique Wealth Strategies reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Unique Wealth Strategies sold 1,854 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $613K.
  • Unique Wealth Strategies first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Unique Wealth Strategies's Alnylam Pharmaceuticals position peaked at $613K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Unique Wealth Strategies's 13F filing for Q2 2026, filed 15 Jul 2026.